Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus
- PMID: 26502220
- PMCID: PMC9617259
- DOI: 10.1001/jamainternmed.2015.5110
Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus
Abstract
Importance: Older patients with diabetes mellitus receiving medical treatment whose blood pressure (BP) or blood glucose level are potentially dangerously low are rarely deintensified. Given the established risks of low blood pressure and blood glucose, this is a major opportunity to decrease medication harm.
Objective: To examine the rate of BP- and blood glucose-lowering medicine deintensification among older patients with type 1 or 2 diabetes mellitus who potentially receive overtreatment.
Design, setting, and participants: Retrospective cohort study conducted using data from the US Veterans Health Administration. Participants included 211 667 patients older than 70 years with diabetes mellitus who were receiving active treatment (defined as BP-lowering medications other than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, or glucose-lowering medications other than metformin hydrochloride) from January 1 to December 31, 2012. Data analysis was performed December 10, 2013, to July 20, 2015.
Exposures: Participants were eligible for deintensification of treatment if they had low BP or a low hemoglobin A1c (HbA1c) level in their last measurement in 2012. We defined very low BP as less than 120/65 mm Hg, moderately low as systolic BP of 120 to 129 mm Hg or diastolic BP (DBP) less than 65 mm Hg, very low HbA1c as less than 6.0%, and moderately low HbA1c as 6.0% to 6.4%. All other values were not considered low.
Main outcomes and measures: Medication deintensification, defined as discontinuation or dosage decrease within 6 months after the index measurement.
Results: The actively treated BP cohort included 211,667 participants, more than half of whom had moderately or very low BP levels. Of 104,486 patients with BP levels that were not low, treatment in 15.1% was deintensified. Of 25,955 patients with moderately low BP levels, treatment in 16.0% was deintensified. Among 81,226 patients with very low BP levels, 18.8% underwent BP medication deintensification. Of patients with very low BP levels whose treatment was not deintensified, only 0.2% had a follow-up BP measurement that was elevated (BP ≥140/90 mm Hg). The actively treated HbA1c cohort included 179,991 participants. Of 143,305 patients with HbA1c levels that were not low, treatment in 17.5% was deintensified. Of 23,769 patients with moderately low HbA1c levels, treatment in 20.9% was deintensified. Among 12,917 patients with very low HbA1c levels, 27.0% underwent medication deintensification. Of patients with very low HbA1c levels whose treatment was not deintensified, fewer than 0.8% had a follow-up HbA1c measurement that was elevated (≥7.5%).
Conclusions and relevance: Among older patients whose treatment resulted in very low levels of HbA1c or BP, 27% or fewer underwent deintensification, representing a lost opportunity to reduce overtreatment. Low HbA1c or BP values or low life expectancy had little association with deintensification events. Practice guidelines and performance measures should place more focus on reducing overtreatment through deintensification.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9617259/bin/nihms-1603979-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9617259/bin/nihms-1603979-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9617259/bin/nihms-1603979-f0003.gif)
Comment in
-
Targeting Vascular Risk Factors in Older Adults: From Polypill to Personalized Prevention.JAMA Intern Med. 2015 Dec;175(12):1949-50. doi: 10.1001/jamainternmed.2015.5941. JAMA Intern Med. 2015. PMID: 26502030 No abstract available.
-
Older patients with diabetes are often overtreated, say researchers.BMJ. 2015 Oct 27;351:h5698. doi: 10.1136/bmj.h5698. BMJ. 2015. PMID: 26508785 No abstract available.
-
Diabetes: Time to rethink intensive treatment for all?Nat Rev Endocrinol. 2016 Jan;12(1):3. doi: 10.1038/nrendo.2015.199. Epub 2015 Nov 20. Nat Rev Endocrinol. 2016. PMID: 26585662 No abstract available.
-
Physicians frequently fail to de-intensify treatment in older patients with diabetes and very low haemoglobin A1c or blood pressure.Evid Based Med. 2016 Aug;21(4):158. doi: 10.1136/ebmed-2016-110462. Epub 2016 Jul 7. Evid Based Med. 2016. PMID: 27388796 Free PMC article. No abstract available.
Similar articles
-
Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes.J Am Geriatr Soc. 2022 Jul;70(7):2019-2028. doi: 10.1111/jgs.17735. Epub 2022 Mar 23. J Am Geriatr Soc. 2022. PMID: 35318647 Free PMC article.
-
Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes.J Am Geriatr Soc. 2020 Apr;68(4):736-745. doi: 10.1111/jgs.16360. Epub 2020 Feb 17. J Am Geriatr Soc. 2020. PMID: 32065387 Free PMC article.
-
Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.J Hypertens. 2019 Oct;37(10):1939-1949. doi: 10.1097/HJH.0000000000002152. J Hypertens. 2019. PMID: 31157748 Review.
-
Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states.Cardiovasc Diabetol. 2018 Feb 12;17(1):27. doi: 10.1186/s12933-018-0673-4. Cardiovasc Diabetol. 2018. PMID: 29433515 Free PMC article.
-
What matters in ADVANCE and ADVANCE-ON.Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x. Diabetes Obes Metab. 2012. PMID: 22118707 Review.
Cited by
-
Clinician and Family Caregiver Perspectives on Deprescribing Chronic Disease Medications in Older Nursing Home Residents Near the End of Life.Drugs Aging. 2024 Apr;41(4):367-377. doi: 10.1007/s40266-024-01110-3. Epub 2024 Apr 4. Drugs Aging. 2024. PMID: 38575748 Free PMC article.
-
Evaluation of deprescription by general practitioners in elderly people with different levels of dependence: cross-sectional study.BMC Prim Care. 2024 Mar 2;25(1):78. doi: 10.1186/s12875-024-02299-3. BMC Prim Care. 2024. PMID: 38431577 Free PMC article.
-
13. Older Adults: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S244-S257. doi: 10.2337/dc24-S013. Diabetes Care. 2024. PMID: 38078580 Review.
-
Metabolic Characteristics of Frail Older People with Diabetes Mellitus-A Systematic Search for Phenotypes.Metabolites. 2023 May 29;13(6):705. doi: 10.3390/metabo13060705. Metabolites. 2023. PMID: 37367862 Free PMC article. Review.
-
Medication misuse and overuse in community-dwelling persons with dementia.J Am Geriatr Soc. 2023 Oct;71(10):3086-3098. doi: 10.1111/jgs.18463. Epub 2023 Jun 5. J Am Geriatr Soc. 2023. PMID: 37272899
References
-
- Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect ofthe transformation of the Veterans Affairs health care system on the quality of care. N Engl J Med. 2003;348(22):2218–2227. - PubMed
-
- Saaddine JB, Cadwell B, Gregg EW, et al..Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med. 2006;144(7):465–474. - PubMed
-
- Kerr EA, Lucatorto MA, Holleman R, Hogan MM, Klamerus ML, Hofer TP; VA Diabetes Quality Enhancement Research Initiative (QUERI) Workgroup on Clinical Action Measures. Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing? Arch Intern Med. 2012;172(12):938–945. - PMC - PubMed
-
- Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259–268. - PubMed